Antibody-dependent enhancement (ADE) is a mechanism by which the pathogenesis of
certain viral infections is enhanced in the presence of sub-neutralizing or cross-reactive non …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human
immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus
have the potential to provide near universal protection against influenza virus infection …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the
integrated HIV genome persists indefinitely within CD4+ T cells and perhaps other cells …